Canada markets close in 2 hours 28 minutes

Sanofi SA (SNW.BE)

Berlin - Berlin Delayed Price. Currency in EUR
Add to watchlist
88.60+0.50 (+0.57%)
As of 08:15AM CEST. Market open.
Full screen
Previous Close88.10
Open88.60
Bid87.34 x 0
Ask87.46 x 0
Day's Range88.60 - 88.60
52 Week Range81.59 - 104.36
Volume16
Avg. Volume19
Market CapN/A
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
All
News
  • GlobeNewswire

    Press Release: Rilzabrutinib LUNA 3 phase 3 study met primary endpoint in immune thrombocytopenia

    Rilzabrutinib LUNA 3 phase 3 study met primary endpoint in immune thrombocytopenia Pivotal data from the first phase 3 study of a BTKi in immune thrombocytopenia (ITP) underscore the potential of rilzabrutinib to provide a clinically meaningful benefit to patients living with ITPRegulatory submissions in the US and EU anticipated by year-endRilzabrutinib is one of 12 potential medicines and vaccines in Sanofi’s robust immunology pipeline and a testament to Sanofi’s ability to successfully accele

  • GlobeNewswire

    Press Release: New 48-week frexalimab phase 2 data support potential for high sustained efficacy in multiple sclerosis

    New 48-week frexalimab phase 2 data support potential for high sustained efficacy in multiple sclerosis Data support frexalimab as a potential first-in-class, high-efficacy, non-lymphocyte depleting treatment for relapsing multiple sclerosis96% of participants receiving high-dose intravenous frexalimab had no new Gd+ T1 lesions and an annualized relapse rate of 0.04 after 48 weeksSanofi has initiated global phase 3 studies of frexalimab in relapsing MS and non-relapsing secondary progressive MS

  • GlobeNewswire

    Sanofi: Information concerning the total number of voting rights and shares - March 2024

    Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’Autorité des Marchés Financiers (Regulation of the French stock market authority) Sanofia French société anonyme with a registered share capital of 2,529,599,938 €Registered office : 46, avenue de la Grande Armée - 75017 Paris - FranceRegistered at the Paris Commercial and Companies Regi